NCT07870369Completed
Cardiovascular Risk in Patients With Primary Hyperparathyroidism
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 77 (actual)
- First submitted
- 6 Oct 2026
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Medical University of Sofia
- NCT number
- NCT07870369
What you commit to
- Study type: Observational
- Participants enrolled: 77
- From 1 Jan 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- secondary hyperparathyroidism
Who the study is looking for
- confirmed primary hyperparathyroidism
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| KPVB Coordinator of this site? Confirm its status | Sofia | Bulgaria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.